Acurx Pharmaceuticals, Inc. ACXP
1.36
0.00
0.00%
as of 25 Sep
- Market cap
- $7.6M
- P/E
- 0.0×
Follow ACXP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (128.11%) | (160.83%) | (270.80%) | (291.07%) |
+8 more TTM periods Free account |
|
| (87.57%) | (104.54%) | (137.98%) | (151.72%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(92.08%) | (106.92%) | (151.21%) | (252.13%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.45) | (2.26) | (4.53) | (4.83) | |
Free Cash Flow |
(6.18) | (6.14) | (6.79) | (7.85) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(32.87%) | (37.77%) | (52.93%) | (82.29%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.82 | 0.82 | 0.85 | 0.86 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.45) | (2.26) | (4.53) | (4.83) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates